PerkinElmer: Driving Innovation and Advancements in Science

Top 10 Pharmaceutical Companies of the Year 2023

PerkinElmer is a global leader in innovative technologies that drive advancements in science and healthcare. The company operates in over 150 countries and has a diverse portfolio of products and services, including diagnostics, life sciences, environmental, and food testing solutions. With a rich history dating back to 1937, PerkinElmer has been at the forefront of scientific breakthroughs, including developing the first commercial atomic absorption spectrometer and playing a key role in the Human Genome Project. In this feature, we explore PerkinElmer’s journey of innovation and highlight the contributions of Joel Goldberg, Senior Vice President of Corporate Development, towards the company’s growth.

On the Way Towards Excellence

PerkinElmer was founded by Richard Perkin and Charles Elmer in 1937 and was initially focused on manufacturing optical instruments, including spectroscopy and microscopy products. The company expanded its product line in the 1960s to include environmental testing solutions, and in the 1970s, it ventured into diagnostics and life sciences. PerkinElmer’s focus on innovation and customer-centric approach has been instrumental in its growth over the years. Today, the company has over 12,500 employees and generated revenue of $3.9 billion in 2020.

Offerings for the World

PerkinElmer’s products and services are focused on four key areas – diagnostics, life sciences, environmental, and food testing. In diagnostics, the company offers a range of solutions for prenatal and neonatal screening, infectious disease testing, and cancer diagnostics. The life sciences division offers products and services for drug discovery, genomics, proteomics, and imaging. PerkinElmer’s environmental solutions include air, water, and soil testing, while its food testing division provides solutions for food safety and quality.

Contribution to Science and Healthcare

PerkinElmer’s commitment to innovation and excellence has resulted in numerous contributions to science and healthcare. In 1962, the company introduced the first commercial atomic absorption spectrometer, which revolutionized elemental analysis in the field of chemistry. PerkinElmer played a significant role in the Human Genome Project and was involved in the sequencing of several chromosomes. The company’s innovative technologies have also contributed to advancements in cancer research and treatment, including the development of a biomarker test that helps identify patients who are likely to benefit from immunotherapy.

Driving Growth with Expertise

Joel Goldberg joined PerkinElmer in 2015 as Senior Vice President of Corporate Development. In this role, he has been responsible for driving the company’s growth through strategic partnerships, mergers and acquisitions, and divestitures. Goldberg has over 20 years of experience in corporate development and has been instrumental in helping PerkinElmer expand its portfolio of solutions and services. Under his leadership, the company has completed several acquisitions, including Tulip Diagnostics, a leading provider of in-vitro diagnostic solutions, and Nexcelom Bioscience, a provider of cell counting and analysis solutions.

Goldberg has also been actively involved in shaping the company’s strategy for growth in emerging markets. In an interview with Forbes, Goldberg emphasized the importance of having a localized approach to doing business in emerging markets, where customer needs and business environments can vary significantly from region to region. His focus on building strong partnerships and understanding the local market dynamics has helped PerkinElmer establish a strong presence in emerging markets, including China and India.

PerkinElmer’s commitment to innovation and customer-centric approach has been instrumental in its growth over the years. The company’s diverse portfolio of products and services has contributed to advancements in science and healthcare, and its focus on strategic partnerships and overall growth remains the driving factor for the company.